Mylan CEO Heather Bresch plans to defend the rising price of EpiPens when testifying before Congress Wednesday, sticking to the company’s effort to shift blame to health insurers and drug-benefit managers.
from WSJ.com: US Business http://ift.tt/2d8FrgL
via IFTTT
No comments:
Post a Comment